Single center experience of a new intensive induction therapy for Ewing's family of tumors: Feasibility, toxicity, and stem cell mobilization properties

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2974-2981

  Strauss, S J ^a   McTiernan, A ^a   Driver, D ^a   Hall Craggs, M ^a   Sandison, A ^a   Cassoni, A M ^a   Kilby, A ^a   Michelagnoli, M ^a   Pringle, J ^a   Cobb, J ^a   Briggs, T ^a   Cannon, S ^a   Witt, J ^a   Whelan, J S ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; MESNA; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EWING SARCOMA; FEASIBILITY STUDY; HUMAN; INFECTION COMPLICATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TUMOR NECROSIS; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; CANCER STAGING; CHILD; FEMALE; MALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DOXORUBICIN; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IFOSFAMIDE; MALE; MESNA; NEOPLASM STAGING; SARCOMA, EWING'S; TREATMENT OUTCOME; VINCRISTINE;

EID: 0041885336     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.106     Document Type: Article

References (33)

1. Ewing J: Diffuse endothelioma of bone. Proc N Y Pathol Soc 21:17-24, 1921
2. Ambros IM, Ambros PF, Strehl S, et al: MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67:1886-1893, 1991
3. Dockhorn-Dworniczak B, Schafer KL, Dantcheva R, et al: Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours. Virchows Arch 425:107-112, 1994
4. Delattre O, Zucman J, Melot T, et al: The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331:294-299, 1994
5. Rosen G, Caparros B, Mosende C, et al: Curability of Ewing's sarcoma and considerations for future therapeutic trials. Cancer 41:888-899, 1978
6. Kinsella TJ, Miser JS, Waller B, et al: Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys 20:389-395, 1991
7. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664-1674, 1990
8. Craft AW, Cotterill SJ, Bullimore JA, et al: Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 33:1061-1069, 1997
9. Jurgens H, Exner U, Gadner H, et al: Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61:23-32, 1988
10. Smith MA, Ungerleider RS, Horowitz ME, et al: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1991
11. Miser JS, Kinsella TJ, Triche TJ, et al: Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J Clin Oncol 6:484-490, 1988
12. Burgert EO Jr, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
13. Skinner R, Sharkey IM, Pearson AD, et al: Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11:173-190, 1993
14. Rosito P, Mancini AF, Rondelli R, et al: Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer 86:421-428, 1999
15. Bacci G, Picci P, Ferrari S, et al: Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase-results of two sequential studies. Cancer 82:1174-1183, 1998
16. Craft A, Cotterill S, Malcolm A, et al: Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 16:3628-3633, 1998
17. Kung F, Hayes FA, Krischer J, et al: Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Invest New Drugs 6:31-36, 1988
18. Miser JS, Kinsella TJ, Triche TJ, et al: Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987
19. Meyer WH, Kun L, Marina N, et al: Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol 10:1737-1742, 1992
20. Paulussen M, Craft AW, Lewis I, et al: Ewing tumor of bone-updated report of the European Intergroup Cooperative Ewing's Sarcoma Study EICESS 92. Proc Am Soc Clin Oncol 21:1568, 2002
21. Gobel V, Jurgens H, Etspuler G, et al: Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 113:187-191, 1987
22. Sauer R, Jurgens H, Burgers JM, et al: Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol 10:101-110, 1987
23. Paulussen M, Ahrens S, Craft AW, et al: Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 16:3044-3052, 1998
24. Picci P, Bohling T, Bacci G, et al: Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol 15:1553-1559, 1997
25. Bacci G, Ferrari S, Bertoni F, et al: Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4-11, 2000
26. Burdach S, Jurgens H, Peters C, et al: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 11:1482-1488, 1993
27. Madero L, Munoz A, Sanchez de Toledo J, et al: Megatherapy in children with high-risk Ewing's sarcoma in first complete remission. Bone Marrow Transplant 21:795-799, 1998
28. Pinkerton CR: Intensive chemotherapy with stem cell support-experience in pediatric solid tumours. Bull Cancer 82:61s-65s, 1995 (suppl 1)
29. Atra A, Whelan JS, Calvagna V, et al: High-dose busulphan/ melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 20:843-846, 1997
30. Meyers PA, Krailo MD, Ladanyi M, et al: High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19:2812-2820, 2001
31. Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS. March, 1998
32. Malcolm AJ, Pringle J, Misdorp W, et al: A Reproducible method of assessing the post-chemotherapy changes in high-grade clinical osteosarcoma, J Pathol, 155:342A, 1988 (abstr)
33. Marina NM, Pappo AS, Parham DM, et al: Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 17:180-190, 1999